Natera, Inc. - Common Stock (OQ:NTRA)
Business Focus: N/A
Apr 11, 2024 08:00 am ET
Apr 08, 2024 08:00 am ET
Apr 05, 2024 07:00 am ET
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’
Apr 01, 2024 08:00 am ET
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 (
Mar 18, 2024 07:00 am ET
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant
Mar 14, 2024 08:00 am ET
Mar 12, 2024 08:00 am ET
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.
Mar 07, 2024 08:00 am ET
Feb 29, 2024 08:00 am ET
Natera to Participate in March Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March.
Feb 28, 2024 04:05 pm ET
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023.
Feb 27, 2024 08:00 am ET
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareDx. The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after
Feb 26, 2024 07:00 am ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting.
Feb 20, 2024 08:00 am ET
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Feb 05, 2024 08:00 am ET
New Study Validates Signatera™ in Endometrial Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in endometrial cancer. The full study can be found
Jan 30, 2024 09:15 am ET
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will continue to grow in the next several years. Multiple myeloma is a type of plasma cell cancer. Normal plasma cells are recognized as an important...
Jan 30, 2024 07:00 am ET
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to risk stratify and detect recurrence early in patients with rese
Jan 29, 2024 07:00 am ET
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement
Jan 25, 2024 07:00 am ET
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™
Jan 22, 2024 07:00 am ET
Natera Acquires Reproductive Health Assets from Invitae
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business.
Jan 22, 2024 06:00 am ET
Invitae Completes Sale of Reproductive Health Assets to Natera
SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).
Jan 18, 2024 08:00 am ET
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 18 – 20, 2024 in San Francis
Jan 16, 2024 05:17 pm ET
Natera Provides Update on Ravgen Trial
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Western District of Texas regarding a patent infringement lawsuit brought by Ravgen, Inc. against Natera.
Jan 09, 2024 07:00 am ET
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following:
Dec 29, 2023 08:00 am ET
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q&A with the investment community at the c
Dec 27, 2023 11:48 pm ET
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. (“NeoGenomics”).
Dec 26, 2023 09:00 pm ET
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Natera, Inc. (NASDAQ: NTRA) on behalf of long-term stockholders following a class action complaint that was filed against Natera on March 10, 2022 with a Class Period from February 26, 2020 to April 19, 2022. Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.
Dec 21, 2023 08:00 am ET
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-info
Dec 11, 2023 12:50 pm ET
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.
Dec 06, 2023 08:30 am ET
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
Nov 14, 2023 08:00 am ET
Natera Announces Real-World Data Collaboration with Merck
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.
Nov 08, 2023 04:05 pm ET
Natera Reports Third Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023.
Nov 08, 2023 09:10 am ET
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG). This international, multi-center, randomized, phase III clinical trial is being conducted by the Europea
Nov 07, 2023 08:30 am ET
Natera to Participate in November Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.
Nov 03, 2023 10:50 pm ET
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Nov 02, 2023 08:30 am ET
Oct 23, 2023 12:18 pm ET
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Natera, Inc.’s Directors and Officers for Breach of Fiduciary Duties – NTRA
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Natera, Inc. (“Natera”) (NASDAQ: NTRA) breached their fiduciary duties to...
Oct 22, 2023 01:00 pm ET
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the ability of the Signatera™ molecular residual disease (MRD) test to help identify patients with resectable colorectal cancer (CRC) who are at an increased risk of recurrence and predict
Oct 20, 2023 10:50 pm ET
NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
NEW ORLEANS, Oct. 20, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Oct 20, 2023 09:00 am ET
Natera to Report its Third Quarter 2023 Results on November 8
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Oct 19, 2023 09:00 am ET
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.
Oct 16, 2023 09:00 am ET
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 European Society for Medical Oncology (ESMO) Congress, taking place Oct. 20-24 in Madrid, Spain.
Oct 06, 2023 02:40 pm ET
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Oct 04, 2023 09:00 am ET
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to detect progression early, with high sensitivity and specificity, and risk stratify patients
Oct 03, 2023 04:43 pm ET
Oct 02, 2023 09:00 am ET
Natera Submits First PMA Module to the FDA for Signatera™
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, as a companion diagnostic (CDx) assay for patien
Sep 18, 2023 09:00 am ET
Natera Announces Senior Leadership Appointments
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
Sep 14, 2023 09:00 am ET
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast canc
Sep 07, 2023 12:09 am ET
Natera Announces Pricing of $250 Million Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 682,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.
Sep 06, 2023 04:24 pm ET
Natera Launches Proposed Follow-On Offering
Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions.
Sep 01, 2023 09:00 am ET
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Aug 16, 2023 09:00 am ET
Aug 03, 2023 04:05 pm ET
Natera Reports Second Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023.
Aug 02, 2023 04:05 pm ET
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA.
Jul 31, 2023 01:39 pm ET
Natera Files Patent Infringement Suit Against NeoGenomics
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay.
Jul 28, 2023 09:00 am ET
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility
Jul 27, 2023 08:00 am ET
Natera to Report its Second Quarter 2023 Results on August 3rd
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Jul 17, 2023 04:47 pm ET
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera in the false advertising case brought by
Jun 06, 2023 08:30 am ET
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA.
Jun 04, 2023 07:08 pm ET
May 30, 2023 08:30 am ET
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 – 6, 2023. Signatera and Natera’s circulating tumor DNA
May 15, 2023 01:48 pm ET
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement
May 09, 2023 04:05 pm ET
Natera Reports First Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.
May 08, 2023 08:00 am ET
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer p
May 02, 2023 08:00 am ET
Natera Announces First Quarter 2023 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Apr 14, 2023 08:00 am ET
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023.
Mar 22, 2023 08:00 am ET
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in
Mar 02, 2023 07:00 am ET
Natera Announces Commercial Payor Coverage for Signatera™
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA te
Feb 28, 2023 04:05 pm ET
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook.
Feb 24, 2023 08:00 am ET
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Feb 23, 2023 08:05 am ET
Feb 21, 2023 08:00 am ET
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Feb 16, 2023 08:00 am ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) that Natera’s Signatera molecular residual disease (MRD) test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer. The coverage applies across all subtypes of the disease, including hormone receptor (HR)-positive, HER2-positive, and triple negative breast cancers. This decision adds to Medicare’s p
Feb 13, 2023 09:28 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Natera, Inc. (NTRA) and Encourages Long-Term NTRA Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Natera, Inc. (NASDAQ: NTRA) on behalf of the company’s long-term investors. Recently a securities fraud complaint was filed against Natera on behalf of certain investors who purchased shares of...
Feb 02, 2023 08:01 am ET
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found
Jan 19, 2023 08:02 am ET
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San
Jan 17, 2023 08:01 am ET
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a
Jan 03, 2023 04:05 pm ET
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET).
Dec 21, 2022 07:23 pm ET
Dec 09, 2022 07:33 am ET
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis
Dec 07, 2022 07:33 am ET
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
AUSTIN, Texas, Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
Dec 06, 2022 04:31 am ET
Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT
Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT
Nov 23, 2022 07:33 am ET
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET).
Nov 21, 2022 07:33 am ET
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved overall survival
Nov 19, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of Natera, Inc. (NASDAQ: NTRA), Butterfly Network, Inc. (NYSE: BFLY), Pulse Biosciences, Inc. (NASDAQ: PLSE), and SunPower Corporation (NASDAQ: SPWR)
Natera, Inc. (NASDAQ: NTRA) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Natera alleging that Defendants misrepresented and/or failed to disclose that: (i) the Company’s Panorama Non-Invasive...
Nov 15, 2022 10:01 pm ET
Natera Announces Pricing of Follow-On Offering
AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.
Nov 15, 2022 03:30 pm ET
Natera Launches Proposed Follow-On Offering
AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be complet
Nov 08, 2022 03:05 pm ET
Natera Reports Third Quarter 2022 Financial Results
AUSTIN, Texas, Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022.
Nov 02, 2022 08:33 am ET
Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs
AUSTIN, Texas, Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective Sept. 15, 2022, with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, to provide minimal residual disease (MRD) and monitoring services with the company's personalized and tumor-informed MRD test, Signatera™.
Nov 01, 2022 11:00 am ET
Natera to Participate in Credit Suisse 31st Annual Healthcare Conference
AUSTIN, Texas, Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9 at 10:25 a.m. PT (1:25 p.m. ET).
Nov 01, 2022 08:30 am ET
Natera to Report its Third Quarter 2022 Results on November 8th
AUSTIN, Texas, Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September 30, 2022, after the market closes on November 8, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Oct 06, 2022 08:33 am ET
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence
Oct 04, 2022 08:33 am ET
Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection
AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta study in Transplantation, found here. The investigators found that in predicting antibody mediated rejection (AMR), donor-derived cell-free DNA (dd-cfDNA) testing with the Prospera Kidney test was superior to the current standard of care, donor-specific antibody (DSA) testing.
Sep 29, 2022 08:33 am ET
Natera Announces 2025 ESG Goals with Publication of 2021 Report
AUSTIN, Texas, Sept. 29, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care. The report, which can be found here, includes the company's 2025 ESG Goals.
Sep 12, 2022 09:27 am ET
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study
Sep 06, 2022 01:32 pm ET
Natera to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Sept. 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the following upcoming investor conferences:
Aug 25, 2022 08:35 am ET
Natera Earns Great Place to Work Certification™ for Second Consecutive Year
AUSTIN, Texas, Aug. 25, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in an independently administered, anonymous survey.
Aug 11, 2022 07:32 am ET
Natera Announces Enrollment Completion for RenaCARE Study
RenaCARE Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease
Aug 10, 2022 04:15 pm ET
Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
AUSTIN, Texas, Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.
Aug 04, 2022 04:05 pm ET
Natera Reports Second Quarter 2022 Financial Results
AUSTIN, Texas, Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook.
Aug 01, 2022 01:13 pm ET
Natera Announces Second Quarter 2022 Earnings Conference Call
AUSTIN, Texas, Aug. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2022, after the market close on August 4, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Jul 18, 2022 01:35 pm ET
Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents
AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September 2021 decision that all three CareDx patents asserted against Natera are invalid for claiming patent-ineligible subject matter.
Jul 18, 2022 08:33 am ET
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer
AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the CMS Molecular Diagnostics Services Program (MolDX) that the Signatera molecular residual disease (MRD) test has met coverage requirements for patients with muscle invasive bladder cancer (MIBC), effective April 19, 2022. To our knowledge, this represents the first coverage expansion to occur under the foundational local coverage determination (LCD) for MRD testing in solid tumors (LCD L38779), which was publishe
Jul 14, 2022 07:33 am ET
Natera Selected for UnitedHealthcare's Preferred Laboratory Network
AUSTIN, Texas, July 14, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced it has been selected to participate in UnitedHealthcare's Preferred Laboratory Network (PLN). Natera's addition to the network was effective July 1, 2022.
Jun 29, 2022 03:39 pm ET
Natera, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit Filed to Recover Investors' Losses; Portnoy Law Firm
The Portnoy Law Firm advises Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) investors that a class action filed on behalf of investors that purchased Natera shares and lost money are encouraged to contact the firm to discuss their legal...
Jun 29, 2022 11:56 am ET
Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
Statistically significant performance improvement from using both dd-cfDNA fraction and dd-cfDNA quantity vs. dd-cfDNA alone
Jun 29, 2022 07:47 am ET
Natera Shareholder Alert: Johnson Fistel, Globally-Recognized Law Firm, Encourages Long-Term Shareholders to Contact the Firm for More Information
Johnson Fistel, LLP is investigating potential claims on behalf of Natera, Inc. (NASDAQ: NTRA) against certain of its officers and directors. If you are a current, long-term shareholder of Natera shares and have continuously held...
Jun 27, 2022 10:16 pm ET
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
NEW YORK, June 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 27, 2022 04:00 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Natera Investors of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 27, 2022 /PRNewswire/ -- Attention Natera, Inc. ("Natera") (NASDAQ: NTRA) shareholders:
Jun 27, 2022 12:30 pm ET
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 27, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 27, 2022 11:45 am ET
DEADLINE ALERT for NTRA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 27, 2022 11:00 am ET
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Natera, Inc. (NTRA) Investors of Class Action and Encourages Investors to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Natera securities between Febraury 26, 2020, and April 19, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 27, 2022 08:30 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, June 27, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 26, 2022 01:45 pm ET
Jun 24, 2022 10:50 pm ET
NATERA 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Natera, Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company’s shares between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
Jun 24, 2022 10:00 pm ET
NTRA FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Natera, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action – NTRA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”), of the important June 27, 2022 lead...
Jun 24, 2022 09:00 pm ET
NATERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Natera, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Natera securities between February 26, 2020 and April 19, 2022, both dates inclusive (the “Class Period”). Investors have until June 27, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 24, 2022 04:00 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Natera, Inc. (NTRA)
The Law Offices of Frank R. Cruz reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Natera, Inc. (“Natera” or the “Company”) (NASDAQ:
Jun 24, 2022 12:00 pm ET
DEADLINE ALERT for IIPR, NTRA, RSKD: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 24, 2022 05:45 am ET
NTRA SHAREHOLDER ALERT: Jakubowitz Law Reminds Natera Shareholders of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 24, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA).
Jun 23, 2022 04:27 pm ET
NTRA 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys Before June 27th Deadline in Securities Class Actio
Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 – Apr. 19, 2022Lead Plaintiff Deadline: June 27, 2022Visit:...
Jun 23, 2022 04:20 pm ET
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 23, 2022 03:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 23, 2022 02:00 pm ET
NTRA Investors Have Opportunity to Lead Natera, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., June 23, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA).
Jun 23, 2022 05:45 am ET
NTRA LAWSUIT ALERT: Levi & Korsinsky Notifies Natera, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 23, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.
Jun 22, 2022 10:47 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Natera, Inc. - NTRA
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company’s shares between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”)....
Jun 22, 2022 04:16 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Natera, Inc. (NTRA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Natera, Inc. (“Natera” or the...
Jun 22, 2022 12:30 pm ET
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Natera
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 22, 2022 08:30 am ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 22, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 22, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Natera, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2022 - (NASDAQ: NTRA)
NEW YORK, June 22, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Natera, Inc..
Jun 21, 2022 10:43 pm ET
NATERA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Natera, Inc. - NTRA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the...
Jun 21, 2022 08:00 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 21, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 21, 2022 05:45 am ET
NTRA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2022 in the Class Action Filed on Behalf of Natera, Inc. Shareholders
NEW YORK, June 21, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.
Jun 20, 2022 04:33 pm ET
Natera, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit Filed to Recover Investors Losses; Portnoy Law Firm
The Portnoy Law Firm advises Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) investors that a class action filed on behalf of investors that purchased Natera shares and lost money are encouraged to contact the firm to discuss their legal...
Jun 20, 2022 11:45 am ET
DEADLINE ALERT for BKKT, IIPR, and NTRA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 20, 2022 10:22 am ET
NTRA & CS Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 20, 2022 10:00 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 20, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Natera Investors of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 20, 2022 /PRNewswire/ -- Attention Natera, Inc. ("Natera") (NASDAQ: NTRA) shareholders:
Jun 20, 2022 01:50 am ET
DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit against Natera, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”)...
Jun 20, 2022 01:20 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
NEW YORK, June 20, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 19, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, Natera, Credit Suisse, and Riskified and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Innovative Industrial Properties, Inc. (NYSE: IIPR), Natera, Inc. (NASDAQ:...
Jun 19, 2022 04:00 pm ET
NTRA FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Natera, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action – NTRA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”), of the important June 27, 2022 lead plaintiff...
Jun 17, 2022 10:50 pm ET
NATERA SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Natera, Inc. - NTRA
NEW ORLEANS, June 17, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company's shares between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
Jun 17, 2022 12:49 pm ET
NTRA 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 – Apr. 19, 2022Lead Plaintiff Deadline: June 27,...
Jun 17, 2022 10:15 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 17, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 17, 2022 05:45 am ET
NTRA SHAREHOLDER ALERT: Jakubowitz Law Reminds Natera Shareholders of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 17, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA).
Jun 16, 2022 06:55 pm ET
Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Natera, Inc.
RADNOR, Pa., June 16, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period").
Jun 16, 2022 11:00 am ET
NTRA Investors Have Opportunity to Lead Natera, Inc. Securities Fraud Lawsuit
LOS ANGELES, June 16, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA).
Jun 16, 2022 10:30 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 16, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ:NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 16, 2022 05:45 am ET
NTRA LAWSUIT ALERT: Levi & Korsinsky Notifies Natera, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 16, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.
Jun 15, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Natera, Inc. - NTRA
CEDARHURST, N.Y., June 15, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company's shares between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). Shareholders have until June 27, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jun 15, 2022 02:15 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Natera, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - NTRA
NEW YORK, June 15, 2022 /PRNewswire/ --
Jun 15, 2022 12:30 pm ET
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Natera
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 15, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Natera, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2022 - (NASDAQ: NTRA)
NEW YORK, June 15, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Natera, Inc..
Jun 14, 2022 11:04 pm ET
NATERA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nat
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera,...
Jun 14, 2022 01:00 pm ET
DEADLINE ALERT for BKKT, IIPR, NTRA, RSKD: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 14, 2022 10:11 am ET
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Investors of Upcoming Lead Plaintiff Deadline
The law firm of Kessler Topaz Meltzer & Check, LLP (
Jun 14, 2022 05:45 am ET
NTRA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2022 in the Class Action Filed on Behalf of Natera, Inc. Shareholders
NEW YORK, June 14, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.
Jun 13, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, Natera, Credit Suisse, and Riskified and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Innovative Industrial Properties, Inc. (NYSE: IIPR), Natera, Inc. (NASDAQ:...
Jun 13, 2022 07:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 13, 2022 06:45 pm ET
NTRA FINAL DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Natera, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action – NTRA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”), of the important June 27, 2022 lead...
Jun 13, 2022 11:45 am ET
DEADLINE ALERT for LICY, BKKT, IIPR, and NTRA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 13, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Natera, Inc. (NTRA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Natera, Inc. (“Natera” or the...
Jun 13, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Natera Investors of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 13, 2022 /PRNewswire/ -- Attention Natera, Inc. ("Natera") (NASDAQ: NTRA) shareholders:
Jun 12, 2022 07:59 pm ET
(NTRA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel about Leading Natera Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Natera, Inc. (“Natera”) (NASDAQ: NTRA) who purchased between February 26, 2020, and April 19, 2022, both dates inclusive...
Jun 12, 2022 07:16 pm ET
NTRA DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP – Important June 27, 2022 Deadline Reminder for Natera, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”)...
Jun 10, 2022 05:45 am ET
NTRA SHAREHOLDER ALERT: Jakubowitz Law Reminds Natera Shareholders of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 10, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA).
Jun 09, 2022 05:45 am ET
NTRA LAWSUIT ALERT: Levi & Korsinsky Notifies Natera, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 9, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.
Jun 08, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Natera, Inc. - NTRA
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company’s shares between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”)....
Jun 08, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Natera, Credit Suisse, Riskified, and Netflix and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Natera, Inc. (NASDAQ: NTRA), Credit Suisse Group AG (NYSE: CS), Riskified Ltd....
Jun 08, 2022 08:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
NEW YORK, June 8, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 08, 2022 12:30 pm ET
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Natera
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 08, 2022 07:33 am ET
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
Includes oral presentation on Prospera test's two-threshold algorithm, showing the combination of donor quantity and donor fraction outperforms donor fraction alone
Jun 08, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Natera, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2022 - (NASDAQ: NTRA)
NEW YORK, June 8, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Natera, Inc..
Jun 07, 2022 11:12 pm ET
NATERA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Natera, Inc. - NTRA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the...
Jun 07, 2022 06:07 pm ET
Moore Kuehn, PLLC Encourages Investors of IRNT and NTRA to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false...
Jun 07, 2022 01:00 pm ET
DEADLINE ALERT for BKKT, IIPR, NTRA, RSKD: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 07, 2022 05:45 am ET
NTRA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2022 in the Class Action Filed on Behalf of Natera, Inc. Shareholders
NEW YORK, June 7, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.
Jun 07, 2022 05:45 am ET
NTRA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2022 in the Class Action Filed on Behalf of Natera, Inc. Shareholders
NEW YORK, June 7, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.
Jun 06, 2022 09:21 pm ET
Jun 06, 2022 11:45 am ET
DEADLINE ALERT for LICY, BKKT, IIPR, and NTRA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 06, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Natera, Inc. (NTRA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Natera, Inc. (“Natera” or the...
Jun 05, 2022 10:50 am ET
NTRA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 27, 2022 Deadline in Securities Fraud Class Action Lawsuit against Natera, Inc.
RADNOR, Pa., June 5, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period").
Jun 05, 2022 12:33 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Natera, Inc. - NTRA
Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 04, 2022 12:18 pm ET
ROSEN, A TOP RANKED FIRM, Encourages Natera, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTRA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”), of the important June 27, 2022 lead...
Jun 03, 2022 10:50 pm ET
NATERA SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Natera, Inc. - NTRA
NEW ORLEANS, June 3, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company's shares between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
Jun 03, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bakkt, IronNet, IIPR, and Natera and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bakkt Holdings, Inc. (NYSE: BKKT), IronNet, Inc. (NYSE: IRNT), Innovative...
Jun 03, 2022 05:00 pm ET
Natera, Inc. Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Important Lead Plaintiff Deadline on June 27, 2022 in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”)...
Jun 03, 2022 05:45 am ET
NTRA SHAREHOLDER ALERT: Jakubowitz Law Reminds Natera Shareholders of a Lead Plaintiff Deadline of June 27, 2022
NEW YORK, June 3, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA).
Jun 02, 2022 01:46 pm ET
NTRA LAWSUIT ALERT: Levi & Korsinsky Notifies Natera, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 2, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.
Jun 02, 2022 11:00 am ET
NTRA Investors Have Opportunity to Lead Natera, Inc. Securities Fraud Lawsuit
LOS ANGELES, June 2, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA).
Jun 01, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Natera, Inc. - NTRA
CEDARHURST, N.Y., June 1, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company's shares between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). Shareholders have until June 27, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jun 01, 2022 04:23 pm ET
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Natera
Did you lose money on investments in Natera? If so, please visit Natera, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jun 01, 2022 11:45 am ET
DEADLINE ALERT for BKKT, IIPR, NTRA, and RSKD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 01, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Natera, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2022 - (NASDAQ: NTRA)
NEW YORK, June 1, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Natera, Inc..
Jun 01, 2022 12:30 am ET
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Natera
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
May 31, 2022 02:00 pm ET
NTRA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2022 in the Class Action Filed on Behalf of Natera, Inc. Shareholders
NEW YORK, May 31, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.
May 31, 2022 12:51 pm ET
IIPR, NTRA & CS Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 31, 2022 12:49 pm ET
Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 – Apr. 19, 2022Lead Plaintiff Deadline: June 27,...
May 31, 2022 11:00 am ET
DEADLINE ALERT for BKKT, IIPR, NTRA, RSKD: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 31, 2022 08:33 am ET
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
NSCLC: ctDNA data in stage I-III patients showed 82% detection pre-treatment and was able to identify 100% of relapses prior to radiographic imaging (5.4 mo lead time) Breast Cancer: Data from the largest longitudinal ctDNA cohort to date (>1100 samples) showed Signatera's ability to detect recurrence with high accuracy across all subtypes Renal Cell: ctDNA dynamics were predictive of treatment outcome in metastatic RCC patients receiving targeted therapy (TKI), after just 6 weeksMerkel Cell: First data showing the ability of Signatera as a surveillance tool in MCC patients regardless of
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.